Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE NeuroMetrix, Inc.
WALTHAM, Mass., Jan. 24, 2014 /PRNewswire/ -- From the moment people learn to walk, many are taught that exercise is the key to living a healthy life. Indeed, the long-term benefits of exercise are indisputable.
However, for those with Type 2 diabetes, exercise isn't just a recreational activity or a way to ward off extra pounds. It's needed to ensure good health overall. Problem is, for the 25 percent of diabetes patients with painful diabetic neuropathy (PDN), the prospect of exercising can be intimidating or a source of anxiety, given the near constant pain PDN triggers in their legs and feet.
This challenge illustrates why a new way of dealing with PDN-the SENSUS™ Pain Management System-has been warmly embraced by doctors and patients. SENSUS was created by NeuroMetrix, Inc., a medical device company located in Waltham, MA. SENSUS offers transcutaneous electrical nerve stimulation.
What's more, SENSUS is lightweight, wearable under clothing and on those walks around the block, and offers non-narcotic pain relief alone or as a complement to other medications. In addition, it has an easy-to-use, one-button control.
"For people with diabetes -especially those with PDN who have led a sedentary lifestyle-having to suddenly incorporate exercise into their daily routine can present a number of formidable challenges," says Shai Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "Add constant pain and it can be a recipe for disaster. The SENSUS Pain Management System can help alleviate pain so people with PDN can get back to the activities they enjoy."
For more information, visit SensusRx.com, who paid for the writing and dissemination of this release.
Contact: Laura Radocaj, Dian Griesel Int'l., 212.825.3210
©2012 PR Newswire. All Rights Reserved.